These findings suggest that lysosomal trafficking genes, including DCTN1, PLEKHM1, ARL8B, and DYNC1I1, could serve as potential predictors of patient outcomes, highlighting the nuanced but potentially decisive role of trafficking machinery in prostate cancer progression and recurrence. This evidence concerns the gene PLEKHM1 and prostate cancer.